|
Eradication of Pneumonococcal Carriage with Sodium Deoxycolate
Application
Antibiotic use of sodium deoxycholate for preventing colonization with Streptococcus pneumoniae and treating pneumococcal infection.
Key Benefits
Effective against antibiotic-resistant pneumococcus.
FDA-approved for use in humans.
Safety already demonstrated in FDA trials for subcutaneous injection to dissolve fat deposits in humans.
Market...
Published: 1/22/2020
Inventor(s): Jorge Vidal
|
|
Virus-Like Particles as RSV Vaccine Candidate
Application
Virus-like particle (VLP) vaccine candidate(s) to prevent respiratory syncytial virus (RSV) infection.
Key Benefits
Candidates may have the most effective anti-viral and anti-inflammatory response.
Potentially protects elderly and immunocompromised patients from re-infection with the RSV virus.
Efficient, tunable and stable production...
Published: 1/15/2020
Inventor(s): Binh Ha, Larry Anderson, Elizabeth Wright
|
|
Mobile Applications for PrEP Participants
Application
Mobile applications to be monitor PrEP adherence and testing results for HIV patients and those at risk of acquiring HIV.
Key Benefits
Delivers push notifications for medication and testing reminders.
Integrates a HIPPA compliant video calling service for remote clinician consultation.
Tracks at-home test kits shipped to participants’...
Published: 12/2/2019
Inventor(s): Aaron Siegler
|
|
Antibacterial Treatment for Gum Disease
Application
Small molecules that inhibit oral bacteria growth to treat gum disease and prevent tooth decay.
Key Benefits
Inhibits S. mutans biofilm formation.
Reduces the number of bacteria by working in a bactericidal, as opposed to bacteriostatic, manner.
Market Summary
Periodontitis is a gum infection in which gums become inflamed due to...
Published: 12/2/2019
Inventor(s): William (Bill) Wuest, Amy Solinski, Marisa Kozlowski, Young Eun Lee, Thomas Paniak, Cristian Ochoa
|
|
Trimeric Immunogen for HIV-1 Vaccination
Application
Trimeric gp120 immunogen that induces broadly cross-reactive V1V2-antibodies for HIV-1 vaccine.
Key Benefits
Possible oral administration.
Broadly cross-reactive against HIV-1 panel.
Promotes antibody responses as both a primary immunogen and boosting immunogen.
Market Summary
Antiretroviral therapy (ART) has dramatically prolonged...
Published: 8/26/2019
Inventor(s): Rama Amara, Andrew Jones, Raghavan Varadarajan, Sannula Kesavardhana
|
|
Antibody Therapy for Varicella Zoster Virus
Application
Human monoclonal antibodies for the treatment of varicella zoster virus (VZV).
Key Benefits
Human monoclonal antibodies can limit the spread of VZV.
gH-specific antibodies are complement-independent.
Market Summary
Varicella Zoster Virus (VZV) causes varicella, more commonly known as chickenpox. Once the illness resolves, the virus...
Published: 8/19/2019
Inventor(s): Rafi Ahmed, Nicole Sullivan
|
|
ADGRB3/BAI3 Knockout Mouse
ApplicationKnockout mouse models for adhesion G protein-coupled receptors B3, brain-specific angiogenesis inhibitor-3 (ADGRB3/BAI3) gene study.Technical SummaryEmory University researchers have developed a knockout mouse model for the ADGRB3/BAI3 gene. Mice were generated by CRISP/cas9 technology on C57Bl6 background. These mice can be used to study...
Published: 7/9/2019
Inventor(s): Erwin Van Meir
|
|
ADGRB1/BAI1 Knockout Mouse
ApplicationKnockout mouse models for adhesion G protein-coupled receptors B1, brain-specific angiogenesis inhibitor-1 (ADGRB1/BAI1) gene study.Technical SummaryEmory University researchers have developed a knockout mouse model for the ADGRB1/BAI1 gene. These mice were developed through homologous recombination and have LacZ gene knock-in. Mice were...
Published: 7/9/2019
Inventor(s): Erwin Van Meir
|
|
Antibodies for Zika and Dengue Viruses
ApplicationsELISAWestern BlotImmunohistochemistrySpecificityHuman monoclonalTechnical SummaryZika Virus (ZIKV) is a mosquito borne filovirus responsible for a 2016-2017 epidemic in North and South America. ZIKV nonstructural protein 1 (NS1) is a pathogenicity factor implicated in virus replication, host interaction and immune invasion. The investigators...
Published: 5/9/2019
Inventor(s): Jens Wrammert, Mark Mulligan
|
|
Human Monoclonal Antibodies Against Ebola Virus
ApplicationAntibodies that bind and neutralize Ebola virus glycoprotein (GP) for use in vaccination or treatment of Ebola virus disease.Key BenefitsHigher binding affinity for Ebola virus GP than closest competitor.Can be used prophylactically or for treatment of Ebola virus disease.Market SummaryThe Ebola virus is an RNA virus with a membrane composed...
Published: 3/26/2019
Inventor(s): Rafi Ahmed
|
Emory UniversityOffice of Technology Transfer